<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2019.83007</article-id><article-id pub-id-type="publisher-id">PI-29804</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20190300000_86326825.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Bavencio (Avelumab)新药的治疗作用研究
  Study on the Therapeutic Effect of New Drug Bavencio (Avelumab)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>天琦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>书杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>辽宁大学药学院，辽宁 沈阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>17</day><month>04</month><year>2019</year></pub-date><volume>08</volume><issue>03</issue><fpage>56</fpage><lpage>61</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   2017年，美国食品药品监督管理局(FDA)加速批准了新药Bavencio，主要成分Avelumab。该药对转移性默克尔细胞癌(mMCC)具有持续缓解作用，它在美国已被加速批准用于治疗成人和12岁儿童的默克尔细胞癌(MCC)。在欧洲，治疗转移性尿路上皮癌生物制剂许可证申请也在接受FDA的优先审查，对于不同癌症治疗正处于发展阶段。本篇文章将讲述该药对于默克尔细胞癌以及转移性尿路上皮癌等几个方面的治疗作用，从药效学，药物动力学，临床试验及副反应等方面进行总结并对Avelumab类新药进行进一步发展进行探讨。 In 2017, the United States FDA approved a number of new drugs, including Bavencio, a major ingredient in Avelum ab. Today we will mainly introduce the development and approval of these new drugs. Avelum abababa Bavencio is an intravenous programmed cell death ligand-1-blocking human antibody which is used in the treatment of various tumors. It has accelerated approval in the United States for the treatment of Merkel’s cell carcinoma in adults and 12-year-old. Treatment of urothelial epithelium in the EU with Avelumab Cancer biologics license applications are being re-viewed by FDA as a priority for different cancer treatments. This article will describe the therapeutic effects of the drug on Merkel’s cell carcinoma and metastatic urothelial carcinoma, summarize the pharmacodynamics, pharmacokinetic and side effects of the drug and discuss the further development of new Avelumab drugs. 
  
 
</p></abstract><kwd-group><kwd>Avelumab，默克尔细胞癌，Pd-L1，JAVELIN200, Avelumab</kwd><kwd> MCC</kwd><kwd> Pd-L1</kwd><kwd> JAVELIN200</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Bavencio (Avelumab)新药的治疗作用研究<sup> </sup></title><p>邱天琦，苏书杰</p><p>辽宁大学药学院，辽宁 沈阳</p><p><img src="//html.hanspub.org/file/3-1710177x1_hanspub.png" /></p><p>收稿日期：2019年4月1日；录用日期：2019年4月15日；发布日期：2019年4月22日</p><disp-formula id="hanspub.29804-formula33"><graphic xlink:href="//html.hanspub.org/file/3-1710177x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>2017年，美国食品药品监督管理局(FDA)加速批准了新药Bavencio，主要成分Avelumab。该药对转移性默克尔细胞癌(mMCC)具有持续缓解作用，它在美国已被加速批准用于治疗成人和12岁儿童的默克尔细胞癌(MCC)。在欧洲，治疗转移性尿路上皮癌生物制剂许可证申请也在接受FDA的优先审查，对于不同癌症治疗正处于发展阶段。本篇文章将讲述该药对于默克尔细胞癌以及转移性尿路上皮癌等几个方面的治疗作用，从药效学，药物动力学，临床试验及副反应等方面进行总结并对Avelumab类新药进行进一步发展进行探讨。</p><p>关键词 :Avelumab，默克尔细胞癌，Pd-L1，JAVELIN200</p><disp-formula id="hanspub.29804-formula34"><graphic xlink:href="//html.hanspub.org/file/3-1710177x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1710177x7_hanspub.png" /> <img src="//html.hanspub.org/file/3-1710177x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>默克尔细胞癌(MCC)是一种被认为是最致命的罕见且具有强侵袭性的神经内分泌皮肤癌，其死亡率是黑色素瘤的三倍，通常发生在暴露阳光下的老年人和免疫抑制的个体中 [<xref ref-type="bibr" rid="hanspub.29804-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref3">3</xref>] 。据统计，全美国每年约1,600人患有Merkel细胞癌。大多数Merkel细胞癌患者的癌细胞可以通过手术进行切除，但有约半数的患者会出现癌症复发。转移性默克尔细胞癌(Mcc)和尿路上皮癌(Uc)的长期治疗表明，目前一线化疗药物正在失去疗效。除了放射治疗和外科治疗外，还有有限的治疗方案可供选择。单克隆抗体等免疫治疗药物的应用被认为是很有前途的。在80%的病例中存在默克尔细胞多瘤病毒(MCV)，并且程序性细胞死亡配体-1(PD-L1)在MCC细胞及周围免疫细胞上表达频繁 [<xref ref-type="bibr" rid="hanspub.29804-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref5">5</xref>] 。Pd-L1与细胞毒性T细胞上的PD受体-1(PD-1)结合，抑制其对肿瘤的杀伤活性，这改变了许多对于肿瘤治疗的手段。MCC有局部复发和局部淋巴结或远处转移的倾向 [<xref ref-type="bibr" rid="hanspub.29804-ref4">4</xref>] ，67%~74%的患者全身转移死亡，通常在发现转移后6个月内死亡。直到目前尚无治疗此类不可切除、复发或转移性MCC的批准治疗方法。鉴于MCC是一种罕见的，但侵袭性皮肤神经内分泌肿瘤的治疗方案有限，使MCC具有孤儿的地位。这也解释了加速批准Avelumab用于转移性MCC患者的原因。2013年至今，药物审批道路迅速发展。从2013年至今，有许多里程碑式发展。2013年1月，JAVELIN方案启动；2014年6月，JAVELIN默克尔200启动；2015年9月，10月，11月依次由FDA进行了孤儿药候选药物认证，快速通道，以及突破疗法设计。2016年6月，EMA孤儿药物设计，EMA验证MAA，同年11月，辉瑞与NCL合作建立CRADA，FDA接受BLA优先审查；2017年，美国加速审批 [<xref ref-type="bibr" rid="hanspub.29804-ref6">6</xref>] 。Avelumab治疗MCC授权申请正在欧盟接受监管审查，澳大利亚、日本和瑞士的第二阶段开发也正在进行中。今年2月，FDA同意优先审查Avelumab在治疗转移性尿路上皮癌中的生物制剂许可证申请 [<xref ref-type="bibr" rid="hanspub.29804-ref7">7</xref>] 。</p></sec><sec id="s4"><title>2. Bavencio基本信息</title><p>Avelumab (Bavencio)是一种静脉注射pd-L1-阻断人抗体，用于成人和12岁儿童默克尔细胞癌 [<xref ref-type="bibr" rid="hanspub.29804-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref10">10</xref>] 。是美国第一次批准的对此病症进行治疗的药物。推荐剂量为静脉滴注10 mg/kg每次60分钟以上，不超过人体承受最大毒性 [<xref ref-type="bibr" rid="hanspub.29804-ref6">6</xref>] 。Bavencio不仅对于默克尔细胞癌的作用效果显著，在欧盟，avelumab治疗尿路上皮癌的生物制剂许可证申请正在接受FDA的优先审查。此外，在全球范围内中的各种合作，avelumab正处于乳腺癌、弥漫性大B细胞淋巴瘤、胃癌、头颈癌、非小细胞肺癌(NSCLC)、卵巢癌和卵巢癌的第三阶段。D期肾细胞癌，子宫内膜癌，妊娠滋养细胞癌，胶质母细胞瘤，肠癌，鼻咽癌，复发性呼吸道乳头状瘤病，胸腺瘤，输卵管癌和腹膜癌的I/II期发展，急性髓性白血病、霍奇金病和实性肿瘤的I期发展 [<xref ref-type="bibr" rid="hanspub.29804-ref8">8</xref>] 。</p></sec><sec id="s5"><title>3. 药效学</title><p>具有阻断PD-L1信号和触发ADCC的双重能力。人IgG1 lambda单克隆抗体与pd-L1的结合，从而阻断Pd-L1与T细胞和抗原提呈细胞上的受体Pd-1和B7.1的相互作用 [<xref ref-type="bibr" rid="hanspub.29804-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref12">12</xref>] 。PD-L1对PD-1和B7.1受体的结合抑制细胞毒性T细胞活性，阻断作用导致免疫应答的恢复(例如抗肿瘤免疫应答)。在同基因小鼠模型中，阻断PD-L1活性导致肿瘤生长减慢 [<xref ref-type="bibr" rid="hanspub.29804-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref14">14</xref>] 。Avelumab的pd-L1相互作用阻断活性被认为是激活T细胞和适应性免疫系统的有效途径。通过保留一个固有的FC-区域，一般认为avelumab参与天然免疫系统并诱导ADCC [<xref ref-type="bibr" rid="hanspub.29804-ref15">15</xref>] 。Avelumab还能通过抗体依赖细胞介导的细胞毒性(ADCC)，在体外诱导自然杀伤细胞介导的肿瘤细胞对多种人肿瘤细胞的杀伤作用 [<xref ref-type="bibr" rid="hanspub.29804-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref17">17</xref>] 。到目前为止，ADCC在临床活动中还没有被证明对avelumab活性起作用。但在临床前模所示中，ADCC可能对avelumab的活性起作用 [<xref ref-type="bibr" rid="hanspub.29804-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref19">19</xref>] 。</p><p>重要的是，尽管avelumab能够介导ADCC，但它似乎不会导致Pd-L1 [<xref ref-type="bibr" rid="hanspub.29804-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref17">17</xref>] 外免疫细胞的耗竭.人外周血单个核细胞在avelumab (0.01~14 μg/mL)作用6或24 h后，细胞因子的释放得到一定程度的诱导 [<xref ref-type="bibr" rid="hanspub.29804-ref17">17</xref>] 。此外，在接受avelumab 10 mg/kg或20 mg/kg的患者中，于输注后48 h测定，促炎细胞因子(TNF-α, IFN-γ, IL-6)水平轻微升高。</p></sec><sec id="s6"><title>4. 药代动力学</title><p>Avelumab每2周接触1~20 mg/kg剂量范围内，1629例在该剂量范围内接受avelumab的患者按比例增加剂量 [<xref ref-type="bibr" rid="hanspub.29804-ref8">8</xref>] 。在输液结束完后1 h内达到最高浓度 [<xref ref-type="bibr" rid="hanspub.29804-ref17">17</xref>] 。每两周重复给药大约4~6周后达到稳定浓度。接受avelumab 10 mg/kg的受试者，稳态分布的平均体积为4.72 L。Avelumab进行蛋白水解降解是其消除的主要机制 [<xref ref-type="bibr" rid="hanspub.29804-ref8">8</xref>] 。在实体肿瘤患者中，接受avelumab 10 mg/kg的患者，其半衰期为6.1 d，全身清除率为0.59 L/d [根据群体药动学分析]。在MCC患者中，avelumab清除率随着时间的推移而降低，与基线相比，平均最大降低率为41.7%。年龄、性别、种族、pd-l1表达状况、肿瘤负担、肾损害的存在情况(轻度、中度或重度)和肝损害(轻度或中度)对avelumab的清除没有临床意义 [<xref ref-type="bibr" rid="hanspub.29804-ref8">8</xref>] 。目前还没有对avelumab进行正式的药物相互作用研究，但考虑到它主要是通过蛋白质分解代谢途径代谢的，因此，此类药物与其他药物之间的相互作用潜能较低 [<xref ref-type="bibr" rid="hanspub.29804-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref21">21</xref>] 。体重与avelumab的全身清除率呈正相关(根据pk群体分析)，严重肝损害对avelumab对pk的影响尚不清楚 [<xref ref-type="bibr" rid="hanspub.29804-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref22">22</xref>] 。</p></sec><sec id="s7"><title>5. 临床研究</title><p>JAVELIN是avelumab的国际临床发展项目，其中包括至少30个临床项目，涉及4000名患者，15种肿瘤类型。avelumab治疗稳期MCC疗效的证据主要来自JAVELIN200II期试验。这些试验的第一项是JAVELIN实体瘤，在Ia期每2周选择Avelumab 10 mg/kg作为进一步研究的剂量。进行剂量扩展部分(阶段Ib)的试验包括16个不同的类型(即范围广泛的晚期固体肿瘤) [<xref ref-type="bibr" rid="hanspub.29804-ref18">18</xref>] ，并将在第三节进一步讨论。根据这次试验的数据，已经开始了一些第二和第三阶段的试验，包括JAVELIN默克尔200，以及FDA批准用于MCCD的Avelumab [<xref ref-type="bibr" rid="hanspub.29804-ref23">23</xref>] 。</p><sec id="s7_1"><title>5.1. 默克尔细胞癌</title><p>治疗与化疗难治性MCC患者进行JAVELIN默克尔200试验(n = 88)。患者的中位年龄为72.5岁(64.5至77.0岁)，MCC诊断后的中位时间为10.4个月(6.3至17.2个月) [<xref ref-type="bibr" rid="hanspub.29804-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref24">24</xref>] ，临床评分0 (56%)或1 (44%)，远处转移用1例(57例)或C2 (31例)。53%的患者存在内脏转移。未根据pd-l1状态选择患者(66%为阳性，18%为阴性，16%不可评估)或MCV状态(52%为阳性，35%为阴性)。而13%的人在基线时无法评估)。患者在1小时内接受静脉输注10 mg/kg，每2周一次，直至疾病进展、不可接受的毒性或其他达到停药原因。在JAVELIN默克尔200，中位跟踪10.4个月(初步分析；数据截止日期为2016年3月3日)，32%的病人有客观反应(9%完全有反应，23%有部分反应)；10%的病人有刺痛反应，36%的患者有进行性疾病 [<xref ref-type="bibr" rid="hanspub.29804-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref27">27</xref>] 。在有的患者中，79%的患者在基线后第一次评估时注意到了反应，而在 82%的患者分析时间。对avelumab的反应发生在PD-L1表达或MCV状态下(亚组后分析)。在随访时，反应的中位持续时间(对进展性疾病或死亡的第一次完全或部分反应)没有达到(2.8至17.5个月)。中位无进展生存期(Pfs)为2.7个月，中位总生存期(OS)为11.3个月 [<xref ref-type="bibr" rid="hanspub.29804-ref7">7</xref>] 。</p></sec><sec id="s7_2"><title>5.2. 其他恶性肿瘤</title><p>在16个不同的扩展队列中，JAVELIN实体瘤(NCT01772004)招募了局部晚期或转移性实体瘤的患者(包括但不包括乳腺癌，胰腺癌，卵巢癌，尿路上皮癌，间皮瘤和非小细胞肺癌) [<xref ref-type="bibr" rid="hanspub.29804-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref28">28</xref>] 。这些患者都不是根据pd-L1的表达来选择的。每2周静脉注射avelumab单抗10 mg/kg，直到病情恶化，不可接受的毒性或其他原因停止 [<xref ref-type="bibr" rid="hanspub.29804-ref23">23</xref>] 。Avelumab在多种肿瘤类型中的初步疗效。例如，在晚期非小细胞肺癌(先前治疗过的) JAVELIN实体瘤组(n = 184)，中位随访8.8个月，50%的患者疾病控制(12%的患者有确诊或(一个病人有完全应答，21个病人有部分反应)，38%的患者有稳定的疾病) [<xref ref-type="bibr" rid="hanspub.29804-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref29">29</xref>] ，无pd-L1表达状态或肿瘤组织学改变。相关临床也表明，avelumab对转移性尿路上皮瘤 [<xref ref-type="bibr" rid="hanspub.29804-ref30">30</xref>] ，晚期肾上腺皮质癌 [<xref ref-type="bibr" rid="hanspub.29804-ref31">31</xref>] ，晚期胸腺上皮瘤 [<xref ref-type="bibr" rid="hanspub.29804-ref32">32</xref>] ，局部进展期或转移TIC乳腺癌 [<xref ref-type="bibr" rid="hanspub.29804-ref33">33</xref>] ，复发性/难治性卵巢–伊恩癌 [<xref ref-type="bibr" rid="hanspub.29804-ref34">34</xref>] ，晚期不可切除间皮瘤也有一定的治疗作用。JAVELIN肾100 (Nct 02493751)是针对日本晚期实体肿瘤患者的一项开放的、多中心的Ib期试验，目的是检查静脉内avelumab与口服阿西替尼作为一线治疗中晚期肾癌患者的情况。每2周服用阿维洛马10毫克/公斤，阿西替尼5毫克，每日两次，有6例患者有数据可查 [<xref ref-type="bibr" rid="hanspub.29804-ref35">35</xref>] 。Avelumab治疗17周，Axitinib治疗16.3周，5例证实部分缓解，1例病情稳定 [<xref ref-type="bibr" rid="hanspub.29804-ref35">35</xref>] 。在实验计量扩展的部分，用于20例晚期胃或胃食管交界腺癌患者，他们每2周接受10 mg/kg阿维鲁单抗的剂量扩张治疗。在中位随访6个月时，根据三例确诊的部分反应，疾病控制率(PR和稳定疾病)为65% [<xref ref-type="bibr" rid="hanspub.29804-ref36">36</xref>] 。</p></sec></sec><sec id="s8"><title>6. 安全性与稳定性</title><p>报告中所报告的数据来自于JAVELIN固体肿瘤研究(n = 1650)和JAVELIN默克尔200的研究(n = 88)中A部分的患者的安全数据的汇总分析(总共为1738) [<xref ref-type="bibr" rid="hanspub.29804-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref35">35</xref>] [<xref ref-type="bibr" rid="hanspub.29804-ref37">37</xref>] 。数据显示，患者接受6次avelumab的注射 [<xref ref-type="bibr" rid="hanspub.29804-ref37">37</xref>] ，24%和7%的患者分别接受avelumab治疗 ≥ 6和 ≥ 12个月 [<xref ref-type="bibr" rid="hanspub.29804-ref18">18</xref>] 。JAVELIN默克尔200研究报告(23个月的中位随访) 18个月的最新分析没有发现新的安全信号 [<xref ref-type="bibr" rid="hanspub.29804-ref35">35</xref>] 。根据来自JAVELIN默克尔200研究B部分患者的可得数据，作为转移性MCC一线治疗的Avelumab具有与汇总分析一致的安全性和耐受性特征。</p><p>临床试验中，avelumab的安全性是可控的。例如，在JAVELIN默克尔200(初步分析)中，70.5%的患者发生了与治疗相关的不良反应(TRAEs)，这占了大多数。其中低度事件占65.9% (1~2级占65.9%，3级占4.5%) [<xref ref-type="bibr" rid="hanspub.29804-ref7">7</xref>] 。最常见的任何级别的TRAE (发生在[10%的病人]是疲劳(24%的病人)和输液相关反应(17%)；这些都是1~2级事件，输液反应一般在使用支持性药物的同一天得到解决。潜在免疫介导的Trae 13%的患者[腹泻、甲亢、甲状腺功能减退、肺炎、1型糖尿病、肾炎、皮疹(均为1级或2级)或3级增加的转氨酶可以控制。6%的患者发生严重TRAE(软骨钙蛋白病、小肠结肠炎、转氨酶升高、输液相关反应、肠道肾炎或滑膜炎)，无治疗相关死亡。Avelumab治疗可导致严重和致命的免疫介导的不良反应 [<xref ref-type="bibr" rid="hanspub.29804-ref8">8</xref>] 。它们可以涉及任何器官系统，一般在治疗中表现出来，也有一些在治疗后出现。在1738例接受标枪实性肿瘤avelumab和JAVELIN默克尔200的患者中，免疫介导的事件包括但不限于肺炎(占患者的1.2%)。NTS)、肝炎(0.9%)、结肠炎(1.5%)、肾上腺功能不全(0.5%)、甲状腺疾病(6%)，1型糖尿病(无其他病因，0.1%)和肾炎(0.1%)；这些副反应包括3~5级不等。同时也存在严重或有生命危险的输液相关疾病的风险 [<xref ref-type="bibr" rid="hanspub.29804-ref7">7</xref>] 。</p></sec><sec id="s9"><title>7. 结论</title><p>临床实验表明，目前avelumab药物虽尚处于发展阶段，但此药物对于默克尔细胞癌和转移性尿路上皮癌都体现了较好的疗效和相对较低的副反应，对于其他疾病治疗作用进一步的发展也仍在探索中，前景十分广阔。</p></sec><sec id="s10"><title>文章引用</title><p>邱天琦,苏书杰. Bavencio (Avelumab)新药的治疗作用研究Study on the Therapeutic Effect of New Drug Bavencio (Avelumab)[J]. 药物资讯, 2019, 08(03): 56-61. https://doi.org/10.12677/PI.2019.83007</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.29804-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Campbell, K., Pustover, K. and Morgan, M.B. (2016) Merkel Cell Carcinoma. In: Crowe, D., Morgan, M., Somach, S. and Trapp, K., Eds., Deadly Dermatologic Diseases: Clinicopathologic Atlas and Text, Springer International Publishing, Berlin, 41-46. https://doi.org/10.1007/978-3-319-31566-9_6</mixed-citation></ref><ref id="hanspub.29804-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lemos, B.D., Storer, B.E., Iyer, J.G., et al. (2010) Pathologic Nodal Evaluation Improves Prognostic Accuracy in Merkel Cell Carcinoma: Analysis of 5823 Cases as the Basis of the First Consensus Staging System. Journal of the American Academy of Dermatology, 63, 751-761. https://doi.org/10.1016/j.jaad.2010.02.056</mixed-citation></ref><ref id="hanspub.29804-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bhatia, S., Afanasiev, O. and Nghiem, P. (2011) Immunobiology of Merkel Cell Carcinoma: Implications for Immunotherapy of a Polyomavirus-Associated Cancer. Current Oncology Reports, 13, 488-497.  
https://doi.org/10.1007/s11912-011-0197-5</mixed-citation></ref><ref id="hanspub.29804-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cassler, N.M., Merrill, D., Bichakjian, C.K., et al. (2016) Merkel Cell Carcinoma Therapeutic Update. Current Treatment Options in Oncology, 17, 36. https://doi.org/10.1007/s11864-016-0409-1</mixed-citation></ref><ref id="hanspub.29804-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Feng, H., Shu-da, M., Chang, Y., et al. (2008) Clonal Integration of a Poly-Omavirus in Human Merkel Cell Carcinoma. Science, 319, 1096-1100. https://doi.org/10.1126/science.1152586</mixed-citation></ref><ref id="hanspub.29804-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Esther, S.K. (2017) Avelumab: First Global Approval.</mixed-citation></ref><ref id="hanspub.29804-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kaufman, H.L., Russell, J., Hamid, O., et al. (2016) Avelumab in Patients with Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma: A Multicentre, Sin-gle-Group, Open-Label, Phase 2 Trial. The Lancet Oncology, 17, 1374-1385.  
https://doi.org/10.1016/S1470-2045(16)30364-3</mixed-citation></ref><ref id="hanspub.29804-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">EMD Serono Inc. and Pfizer Inc. (2017) Bavencio® (avelumab) Injection: US Prescribing Information.</mixed-citation></ref><ref id="hanspub.29804-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">US FDA (2017) FDA Approves First Treatment for Rare Form of Skin Cancer. https://www.fda.gov</mixed-citation></ref><ref id="hanspub.29804-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">EMD Serono (2017) EMD Serono—About Us. http://www.emdserono.com</mixed-citation></ref><ref id="hanspub.29804-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pfizer (2016) European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Car-cinoma [Media Release]. http://www.pfizer.com</mixed-citation></ref><ref id="hanspub.29804-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Adis Insight (2017) Drug Profile: Avelumab. http://adisinsight.springer.com</mixed-citation></ref><ref id="hanspub.29804-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Merck KGaA (2014) Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Acceler-ate Presence in Immuno-Oncology. http://www.businesswire.com</mixed-citation></ref><ref id="hanspub.29804-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Pfizer (2014) Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology [Media Re-lease]. http://www.pfizer.com</mixed-citation></ref><ref id="hanspub.29804-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Pfizer (2016) Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer [Media Release]. http://www.pfizer.com</mixed-citation></ref><ref id="hanspub.29804-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Boyerinas, B., Jochems, C., Fantini, M., et al. (2015) Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunology Research, 3, 1148-1157.  
https://doi.org/10.1158/2326-6066.CIR-15-0059</mixed-citation></ref><ref id="hanspub.29804-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fujii, R., Friedman, E.R., Richards, J., et al. (2016) Enhanced Killing of Chor-doma Cells by Antibody-Dependent Cell-Mediated Cytotoxicity Employing the Novel Anti-PD-L1 Antibody Avelumab. Oncotarget, 7, 33498-33511.  
https://doi.org/10.18632/oncotarget.9256</mixed-citation></ref><ref id="hanspub.29804-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency (2017) European Public Assessment Report: Bavencio (Avelumab).  
http://www.ema.europa.eu</mixed-citation></ref><ref id="hanspub.29804-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Heery, C.R., O’Sullivan-Coyne, G., Madan, R.A., et al. (2017) Avelumab for Metastatic or Locally Advanced Previously Treated Solid Tumours (JAVELIN Solid Tumor, a Phase 1a, Multicohort, Dose-Escalation Trial. The Lancet Oncology, 18, 587-598.</mixed-citation></ref><ref id="hanspub.29804-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency (2018) Bavencio (Avelumab, Summary of Product Characteristics).  
http://www.ema.europa.eu</mixed-citation></ref><ref id="hanspub.29804-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Pfizer (2016) Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer [Media Release]. http://www.pfizer.com</mixed-citation></ref><ref id="hanspub.29804-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Pfizer (2015) Avelumab Fact Sheet. https://www.pfizer.com</mixed-citation></ref><ref id="hanspub.29804-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Heery, C.R., O’Sullivan-Coyne, G., Madan, R.A., et al. (2017) Avelumab for Metastatic or Locally Ad-vanced Previously Treated Solid Tumours (JAVELIN Solid Tumor, a Phase 1a, Multicohort, Doseescalation Trial. The Lancet Oncol-ogy, 45, 39. https://doi.org/10.1016/S1470-2045(17)30239-5</mixed-citation></ref><ref id="hanspub.29804-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Grenga, I., Donahue, R.N., Lepone, L.M., et al. (2016) A Fully Human IgG1 Anti-PD-L1 MAb in an in Vitro Assay Enhances Antigen-Specific T-Cell Responses. Clinical &amp; Translational Immu-nology, 5, e83.  
&lt;br&gt;https://doi.org/10.1038/cti.2016.27</mixed-citation></ref><ref id="hanspub.29804-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Transgene (2016) Transgene Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head and Neck Cancer in a Phase 1/2 Study [Media Release]. http://www.transgene.fr</mixed-citation></ref><ref id="hanspub.29804-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Vaccinex (2016) Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer [Media Release].  
http://www.vaccinex.com</mixed-citation></ref><ref id="hanspub.29804-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Pfizer (2016) Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers [Media Release]. http://www.pfizer.com</mixed-citation></ref><ref id="hanspub.29804-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Debiopharm (2016) Debiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy [Media Release]. &lt;br&gt;https://www.debiopharm.com</mixed-citation></ref><ref id="hanspub.29804-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Pfizer (2017) FDA Grants Approval for BAVENCIO®(Avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma [Media Release]. http://www.pfizer.com</mixed-citation></ref><ref id="hanspub.29804-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kelly, K., Heery, C.R., Patel, M.R., et al. (2016) Avelumab (MSB0010718C; anti-PD-L1) in Patients with Advanced Cancer: Safety Data from 1300 Patients Enrolled in the Phase 1b JAVELIN Solid Tumor Trial. Journal of Clinical Oncology, 34, 3055-3055.</mixed-citation></ref><ref id="hanspub.29804-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Gulley, J.L., Rajan, A., Spigel, D.R., et al. (2017) Avelumab for Patients with Previously Treated Metastatic or Recurrent Non-Small-Cell Lung Cancer (JAVELIN Solid Tumor, Dose-Expansion Cohort of a Multicentre, Open-Label, Phase 1b Trial. The Lancet Oncology, 52, 323-329. &lt;br&gt;https://doi.org/10.1016/S1470-2045(17)30240-1</mixed-citation></ref><ref id="hanspub.29804-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">U.S. (2017) Food and Drug Administration. Avelumab (BAVENCIO). &lt;br&gt;https://www.fda.gov</mixed-citation></ref><ref id="hanspub.29804-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Verschraegen, C.F., Chen, F., Spigel, D.R., et al. (2016) Avelumab (MSB0010718C; anti-PD-L1) as a First-Line Treatment for Patients with Advanced NSCLC from the JAVELIN Solid Tumor Phase 1b Trial: Safety, Clinical Activity, and PD-L1 Expression. Journal of Clinical Oncology, 34, 9036-9036.</mixed-citation></ref><ref id="hanspub.29804-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">US FDA (2017) Bavencio®Avelumab, US Prescribing Infor-mation. http://www.fda.gov</mixed-citation></ref><ref id="hanspub.29804-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">D’Angelo, S.P., Russell, J., Lebbe, C., et al. (2018) Efficacy and Safety of First-Line Avelumab Treatment in Patients with Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA On-cology, 4, e180077. &lt;br&gt;https://doi.org/10.1001/jamaoncol.2018.0077</mixed-citation></ref><ref id="hanspub.29804-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">D’Angelo, S.P., Russell, J.S., Bhatia, S., et al. (2018) 18-Month Efficacy and Safety Update from JAVELIN Merkel 200 Part A: A Phase II Study of Avelumab in Metastatic Merkel Cell Carcinoma Progressed Onchemotherapy [Abstract No. 192 plus Poster]. Journal of Clinical Oncology, 36, 192.</mixed-citation></ref><ref id="hanspub.29804-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Kelly, K., Infante, J.R., Taylor, M.H., et al. (2018) Safety Profile of Avelumab in Patients with Advanced Solid Tumors: A Pooled Analysis of Data from the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel200 Clinical Trials. Cancer, 124, 2010-2017. &lt;br&gt;https://doi.org/10.1002/cncr.31293</mixed-citation></ref></ref-list></back></article>